A phase I clinical and pharmacokinetic study of the topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days.

摘要: Topotecan (SKF only the closed, lactone form is active. The predominated during infusion, with hydrolysis occurring rapidly following end of infusion. There were linear relationships between dose administered and peak plasma concentrations as well AUC to total. was cleared from a total body clearance 25.7 (+/- 6.7) l/h/m2. concentration declined harmonic mean terminal half-life 3.4 1.1)h. Lactone renal excretion major routes elimination.(ABSTRACT TRUNCATED AT 250 WORDS)